4.2 Article

Manganese exposure, parkinsonian signs, and quality of life in South African mine workers

期刊

AMERICAN JOURNAL OF INDUSTRIAL MEDICINE
卷 63, 期 1, 页码 36-43

出版社

WILEY
DOI: 10.1002/ajim.23060

关键词

manganese; miners; parkinsonian disorders

资金

  1. National Institute of Environmental Health Sciences [K01ES028295, K24ES017765, R01ES026891, R21ES01750, R21ES017504]
  2. American Parkinson Disease Association
  3. Association of Commonwealth Universities

向作者/读者索取更多资源

Background Manganese (Mn) neurotoxicity is associated with parkinsonism; the associated motor deficits can affect individuals' quality of life (QoL). We investigated associations between Mn exposure, parkinsonian signs, and QoL in Mn mine workers. Methods We assessed parkinsonian signs and QoL in 187 black South African Mn mine workers, using the Unified Parkinson Disease Rating Scale motor subsection 3 (UPDRS3) and the Parkinson Disease Questionnaire (PDQ-39), respectively. We estimated cumulative Mn exposure in mg Mn/m(3)-years using complete occupational histories and a job-exposure matrix. We investigated the cross-sectional association between cumulative Mn exposure and UPDRS3 score, and the UPDRS3 score and PDQ-39, adjusting for age, using linear regression. Results Participants' mean age was 41.8 years (range, 21-67 years); 97.3% were male. Estimated mean cumulative Mn exposure at the time of examination was 5.4 mg Mn/m(3)-years, with a mean of 14.0 years working in a Mn mine. The mean UPDRS3 score was 10.1 and 25.7% of the workers had a UPDRS3 score greater than or equal to 15. There was a U-shaped dose-response relation between cumulative Mn exposure and UPDRS3 score, with a positive association up to 15 mg Mn/m(3)-years of exposure and an inverse association thereafter. Greater UPDRS3 scores were associated with poorer self-reported QoL. Conclusion In this cohort of employed Mn mine workers, parkinsonian signs were common and were associated with both estimated cumulative Mn exposure and poorer QoL.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial

Rozalina Dimitrova, Heakyung Kim, Jill Meilahn, Henry G. Chambers, Brad A. Racette, Marcin Bonikowski, Eun Sook Park, Emily McCusker, Chengcheng Liu, Mitchell F. Brin

Summary: OnabotulinumtoxinA is safe and effective in reducing lower limb spasticity and improving functional outcomes in children with cerebral palsy.

NEUROREHABILITATION (2022)

Article Environmental Sciences

Occupational Hearing Loss for Platinum Miners in South Africa: A Case Study of Data Sharing Practices and Ethical Challenges in the Mining Industry

Liepollo Ntlhakana, Gill Nelson, Katijah Khoza-Shangase, Elton Dorkin

Summary: This study demonstrates that strict protection of employee medical data can hinder research. Clear policies should be developed to improve the sharing of workers' records in the mining industry and enhance the work of healthcare professionals (HCPs).

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Article Neurosciences

Environmental manganese exposure and cognitive control in a South African population

Brad A. Racette, Gill Nelson, Wendy W. Dlamini, Tamara Hershey, Pradeep Prathibha, Jay R. Turner, Harvey Checkoway, Lianne Sheppard, Susan Searles Nielsen

Summary: Residence in a community near a high manganese emission source is associated with cognitive dysfunction, including aspects of cognitive control as assessed by the Go-No-Go test.

NEUROTOXICOLOGY (2022)

Article Clinical Neurology

Incidence of amyotrophic lateral sclerosis in older adults

Alejandra Camacho-Soto, Susan Searles Nielsen, Irene M. Faust, Robert C. Bucelli, Timothy M. Miller, Brad A. Racette

Summary: This study aimed to investigate the incidence and survival rates of amyotrophic lateral sclerosis (ALS) in Medicare beneficiaries aged 66 to 90. The findings suggest that older and marginalized ALS patients are less likely to be accurately diagnosed and included in epidemiological studies.

MUSCLE & NERVE (2022)

Article Biochemistry & Molecular Biology

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial

Andrew Feigin, Elizabeth E. Evans, Terrence L. Fisher, John E. Leonard, Ernest S. Smith, Alisha Reader, Vikas Mishra, Richard Manber, Kimberly A. Walters, Lisa Kowarski, David Oakes, Eric Siemers, Karl D. Kieburtz, Maurice Zauderer

Summary: The SIGNAL Phase 2 study of pepinemab immunotherapy in early Huntington's disease (HD) did not meet its coprimary clinical efficacy endpoints, but had a favorable safety profile and showed a significant treatment-related reduction in caudate brain atrophy and reversal of the characteristic decline in brain metabolic activity that is typical of HD progression.

NATURE MEDICINE (2022)

Article Clinical Neurology

The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study

Samuel Frank, Claudia Testa, Mary C. Edmondson, Jody Goldstein, Elise Kayson, Blair R. Leavitt, David Oakes, Christine O'Neill, Christina Vaughan, Jacquelyn Whaley, Nicholas Gross, Mark Forrest Gordon, Juha-Matti Savola

Summary: This study evaluated the long-term safety and tolerability of deutetrabenazine for the treatment of Huntington disease. The results showed that adverse events observed with long-term deutetrabenazine exposure were consistent with previous studies. Reductions in chorea persisted over time and there was no unexpected worsening of chorea upon treatment cessation.

CNS DRUGS (2022)

Correction Biochemistry & Molecular Biology

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial (Aug, 10.1038/s41591-022-01919-8, 2022)

Andrew Feigin, Elizabeth E. Evans, Terrence L. Fisher, John E. Leonard, Ernest S. Smith, Alisha Reader, Vikas Mishra, Richard Manber, Kimberly A. Walters, Lisa Kowarski, David Oakes, Eric Siemers, Karl D. Kieburtz, Maurice Zauderer

NATURE MEDICINE (2022)

Article Clinical Neurology

Protective Effects of Lovastatin in a Population-Based ALS Study and Mouse Model

Collin J. Kreple, Susan Searles Nielsen, Kathleen M. Schoch, Tao Shen, Mark Shabsovich, Yizhe Song, Brad A. Racette, Timothy M. Miller

Summary: This study used a combined pharmacoepidemiologic and ALS mouse model approach to identify potential motor neuron protective medications. The results showed an inverse dose-response association between lovastatin and ALS, and confirmed the neuroprotective effects of lovastatin in a mouse model by delaying symptom onset, prolonging survival, and preserving motor neurons.

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

Neocortical Lewy Body Pathology Parallels Parkinson's Dementia, but Not Always

W. R. Wayne Martin, John R. Younce, Meghan C. Campbell, Brad A. Racette, Scott A. Norris, Mwiza Ushe, Susan Criswell, Albert A. Davis, Isabel Alfradique-Dunham, Baijayanta Maiti, Nigel J. Cairns, Richard J. Perrin, Paul T. Kotzbauer, Joel S. Perlmutter

Summary: This study investigates the relationship between Parkinson's disease (PD) with dementia and cortical proteinopathies. The study finds that neocortical Lewy bodies are commonly present in PD patients with dementia, but also appear in those without dementia. Other factors may contribute to PD dementia, aside from the classic neuropathological features.

ANNALS OF NEUROLOGY (2023)

Article Neurosciences

Incidence of Parkinson disease in North America

A. W. Willis, E. Roberts, J. C. Beck, B. Fiske, W. Ross, R. Savica, S. K. Van den Eeden, C. M. Tanner, C. Marras

Summary: Parkinson's disease is the second most common age-related neurodegenerative condition in North America, with a higher prevalence than previously reported. Age and gender affect the incidence rate, with males having a higher risk. Incidence estimates vary across different data sources, possibly due to factors such as case ascertainment, diagnosis methods, genetic risk factors, exposure to environmental toxins, and geographic location.

NPJ PARKINSONS DISEASE (2022)

Article Public, Environmental & Occupational Health

A predictive algorithm to identify ever smoking in medical claims-based epidemiologic studies

Irene Faust, Mark Warden, Alejandra Camacho-Soto, Brad A. Racette, Susan Searles Nielsen

Summary: This study developed and validated an algorithm to estimate the probability of ever smoking using administrative claims data. The algorithm was applied to a large sample of Medicare beneficiaries and showed promising results in approximating smoking behavior for epidemiologic analyses.

ANNALS OF EPIDEMIOLOGY (2023)

Article Multidisciplinary Sciences

Biologic targets of prescription medications and risk of neurodegenerative disease in United States Medicare beneficiaries

Yizhe Song, Brad A. Racette, Alejandra Camacho-Soto, Susan Searles Nielsen

Summary: According to the medication data, the use of xanthine dehydrogenase/oxidase blockers (such as allopurinol) may be associated with a lower risk of Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.

PLOS ONE (2023)

Article Public, Environmental & Occupational Health

Exposure of formal and informal nail technicians to organic solvents found in nail products

Goitsemang Keretetse, Gill Nelson, Derk Brouwer

Summary: This study aimed to assess the exposure of nail technicians to volatile organic compounds (VOCs) in South Africa and provide a task-based exposure assessment. The study found differences in VOC concentrations between formal and informal nail technicians, with informal technicians exposed to higher CO2 concentrations and formal technicians exposed to higher TVOC concentrations. The study highlights the importance of understanding the health effects on nail technicians and the often-overlooked informal sector in this industry.

FRONTIERS IN PUBLIC HEALTH (2023)

Article Neurosciences

Neuroinflammation and white matter alterations in occupational manganese exposure assessed by diffusion basis spectrum imaging

Susan R. Criswell, Susan Searles Nielsen, Irene M. Faust, Joshua S. Shimony, Robert L. White III, Jason Lenox-Krug, Brad A. Racette

Summary: This study evaluated the neuroinflammation and white matter microstructural integrity in individuals with occupational manganese exposure. The findings showed that welders with manganese exposure had higher indicators of neuroinflammation-related cellularity, greater extracellular edema, and lower apparent axonal density in multiple white matter tracts, suggesting a neuroinflammatory component in the pathophysiology of manganese neurotoxicity.

NEUROTOXICOLOGY (2023)

暂无数据